[Source: Small Cap Network] – Not long ago, shortly after he started his company, CEO Michael Wilhelm was scrambling to find a name for his biotech focused, wholly owned subsidiary of IR Biosciences Holdings Inc..
“When we started the company, I asked the doctor (who first stumbled upon the discovery of the compound), Explains Wilhelm. ‘What do you think the drug does?'”
“I think it does something with the immune system,” he said. “It must, because anytime there is a compromised animal, that’s exposed to JP-8 jet fuel (radiation) and exposed to Influenza we seem to rev it up.”
Wilhelm decided on the name ImmuneRegen – Immune Regeneration- and it turned out to be a great thing after now identifying the mechanisms of the compound. “We were on the money. We modulate the immune system and we can tell you how you how we do that using Dendritic cell honing and things of that nature.”
For more information: ImmuneRegen gaining attention for its stem cell active compound